2-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one | 56347-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one
• 英文别名: 2-Methyl-7H-1,3,4-thiadiazolo[3,2-a]pyrimidin-7-one；2-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one
• CAS: 56347-07-0
• 化学式: C₆H₅N₃OS
• 分子量: 167.191
• InChiKey: MIWYXIQTARQIRR-UHFFFAOYSA-N

物化性质

• 熔点：
  207-208 °C(Solv: ethanol (64-17-5))
• 沸点：
  274.9±23.0 °C(Predicted)
• 密度：
  1.62±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  70.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-methyl-7-oxo-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidine-5-carboxylic acid 生成 2-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one
  参考文献：
  名称：

  硒杂环。XV。† 2-氨基硒唑和2-氨基-1,3,4-硒二唑与炔属化合物的反应

  摘要：

  用丙酸乙酯或乙炔二甲酸二甲酯的2-氨基硒唑得到7 H-硒代氮杂[3，2 - a ]嘧啶-7-酮。2-氨基-1,3,4-硒代二唑与乙酰二羧酸二甲酯得到7 H -1,3,4-硒代重氮[3,2 - a ]嘧啶-7-；用丙酸乙酯反应时，反应路线不寻常，分离出2-甲乙氧基-5 H-硒代苯并[3，2 - a ]嘧啶-5-酮。光谱分析支持结构的分配。

  DOI：

  10.1002/jhet.5570120413

文献信息

• New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
  申请人：Abe Hiroyuki

  公开号：US20080081818A1

  公开（公告）日：2008-04-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的化合物，其中每个符号如规范中定义，或其药学上可接受的盐，或其溶剂化合物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，并且可用作预防或治疗丙型肝炎的药剂。
• Synthesis of 1,3,4-thiadiazolo[3,2-α]pyrimidin-5-one and isomeric 7-one derivatives
  作者：Filippo Russo、Andrea Santagati、Maria Santagati

  DOI：10.1002/jhet.5570220212

  日期：1985.3

  Continuing preceeding studies, designed to obtain derivatives of 1,3,4-thiadiazolo[3,2-α]pyrimidin-5-one and of the isomeric 7-one of pharmacological interest, some of the above mentioned compounds were prepared. Their structural identification was obtained by mass spectra.

  为了获得1,3,4-噻二唑并[3,2-α]嘧啶-5-酮和7-异构体之一的衍生物，我们进行了继续的研究，制备了上述化合物中的一些。它们的结构鉴定是通过质谱获得的。
• NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR
  申请人：Abe Hiroyuki

  公开号：US20120107273A1

  公开（公告）日：2012-05-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由下式[I]表示的化合物，其中每个符号如规范所定义，或其药学上可接受的盐，或其溶剂化物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性表现出抗HCV活性，可作为预防或治疗丙型肝炎的药剂。
• Cephalosporin derivatives
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0164944A1

  公开（公告）日：1985-12-18

  (57) A cephalosporin derivative of the formula I: in which X is S, O, CH2 or SO, represents one of C-7 acyl groups known in the cephalos porin art, R3 is hydrogen or methoxy, R4 is hydrogen, optionally substituted alkyl or allyl, and R5 is an aromatic heterocyclic ring system which is linked via carbon, and which contains a quaternised nitrogen atom.

  (57) 式 I 的头孢菌素衍生物： 其中 X 是 S、O、CH2 或 SO、 代表头孢菌素领域已知的 C-7 乙酰基之一，R3 是氢或甲氧基，R4 是氢、任选取代的烷基或烯丙基，R5 是通过碳连接的芳香杂环系统，其中包含一个季铵化氮原子。
• NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Japan Tobacco, Inc.

  公开号：EP2009004A1

  公开（公告）日：2008-12-31

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及下式[I]所代表的化合物 其中各符号如说明书中所定义，或其药学上可接受的盐，或其溶液，以及含有该化合物的抗HCV药剂和HCV聚合酶抑制剂。本发明的化合物具有基于 HCV 聚合酶抑制活性的抗 HCV 活性，可用作丙型肝炎的预防或治疗剂。